The Filing Desk

KORU Medical Systems

KRMD · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

KRMD · Last close · November 19, 2026
$3.44
Value KORU Medical Systems yourself

KORU Medical Systems' revenue rose 22.2% to $41 million in fiscal 2025. Its operating margin was −7.2%, up from −19.2% a year earlier. Free cash flow was −$0 million. The diluted share count rose 0.8%.

KORU Medical Systems, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 12, 2026 · 0001161697-26-000052 Updated
Revenue
$41M
22.2%
Operating margin
−7.2%
11.9 pts
Net income
−$3M
 
Free cash flow
−$0M
 
Return on equity
−15.6%
17.1 pts
Market cap
$161M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What KORU Medical Systems does

KORU Medical makes and sells devices that deliver drugs by infusion under the skin, called subcutaneous infusion, in large volumes. Its main product line is the FREEDOM Infusion System, which includes syringe drivers, needle sets and flow-rate tubing. The system is used mostly to give immunoglobulin therapy to people with primary immunodeficiency diseases and chronic inflammatory demyelinating polyneuropathy, a nerve disorder. Patients can use it at home or in infusion centers.

The company gets revenue from three sources: its domestic core business in the United States and Canada, its international core business, and pharma services and clinical trials. The core revenue is from sales of syringe drivers, tubing and needles. Pharma services revenue comes from supplying devices for clinical trials of drugs, and from engineering work to customize the system for drug makers.

It says it aims to deepen its place in subcutaneous immunoglobulin and extend into other new subcutaneous drug therapies. It was incorporated in 1980.

Its biggest risks, as it describes them

  • Failing to bring out new products or keep up with changing technology.
  • Its business depends on a supply of drugs, such as plasma-based immunoglobulin products, that its devices deliver.
  • Changes in FDA approvals for the drugs, or new therapies that need no device, could reduce demand.
  • The markets for its products may be smaller than it estimates.
From KORU Medical Systems's annual report on Form 10-K, filed March 12, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2019, earnings per share fell 20.6% a year and net income 9.1% a year, as new shares raised the share count by 3% and diluted each share's earnings. KORU Medical Systems then lost money in fiscal 2020, 2021, 2022, 2023, 2024 and 2025.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments251712109
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage−530.9x−378.4x−202.0x−89.6x−53.5x
Current ratio7.8x4.3x4.5x2.7x2.4x
Quick ratio6.5x3.4x3.8x2.3x2.0x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project KORU Medical Systems' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What KORU Medical Systems says to expect

  • Full year 2026: revenueRevising full-year 2026 revenue guidance to $48.0 - $48.5 million, representing year-over-year growth of 17% - 18%, compared to the previous guidance range of $47.5 - $48.5 million.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 10, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $241,615 of KORU Medical Systems shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 13, 2026Eric SchillerChief Technology OfficerBought8,546$3.63$31,022Form 4
Sep 8, 2026Adam R KalbermattenChief Commercial OfficerBought32,000$3.16$101,120Form 4
Jun 11, 2026Adam R KalbermattenPresident-Chief Commercial OffBought12,500$3.94$49,275Form 4
May 18, 2026Eric SchillerChief Technology OfficerBought5,000$3.91$19,550Form 4
May 14, 2026Thomas Edward AdamsChief Financial OfficerBought5,500$3.86$21,248Form 4
May 14, 2026Christopher PazdanChief Operating OfficerBought5,000$3.88$19,400Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−17.7%13.2%21.1%
Altman Z''1.18−0.54−0.06
Accruals ratio−25.0%−20.6%−11.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailPass
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio rosePassFailFail
Share count didn't riseFailFailFail
Gross margin rosePassPassFail
Revenue rose relative to assetsFailPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put KORU Medical Systems side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
KORU Medical SystemsFY2522.2%−7.2%−1.1%———
MyomoFY2525.7%−35.2%−39.7%——3Compare
PulsenmoreFY25314.3%—−82.5%———Compare
SS Innovations InternationalFY25105.7%−19.3%−52.3%———Compare
Utah Medical ProductsFY25−5.8%29.6%37.2%26.8%−6.0x6Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue12121723242428283441
Revenue growth8.9%0.4%41.2%33.5%4.4%−2.8%18.8%2.2%18.0%22.2%
Gross profit881115151415172126
Research and development0001125654
Operating income1−111−1−7−11−10−6−3
Net income1−011−1−5−9−14−6−3
Diluted EPS (US$)0.02−0.010.020.01−0.03−0.10−0.19−0.30−0.13−0.06
Diluted shares (millions)38383939424445464646
Cash flow
Cash from operations2−020−1−4−5−5−00
Capital expenditure0000103111
Free cash flow2−110−2−5−8−6−2−0
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation0001233333
Balance sheet at fiscal year end
Cash and short-term investments434627251712109
Debt incl. finance leases——————————
Total assets881014404142282728
Total liabilities1223451181011
Shareholders' equity77911363631201717
Margins and ratios
Gross margin62.1%61.6%62.3%64.1%61.8%58.6%55.1%58.6%63.4%62.3%
Operating margin9.7%−6.0%6.7%2.5%−5.2%−29.9%−38.6%−36.0%−19.2%−7.2%
Net margin6.4%−4.3%5.2%2.4%−5.0%−19.4%−31.1%−48.2%−18.0%−6.4%
Free cash flow margin14.6%−4.3%6.8%0.5%−6.9%−19.9%−29.3%−19.9%−4.8%−1.1%
Rule of 40 (growth + FCF margin)23.6%−4.0%48.0%34.0%−2.5%−22.7%−10.5%−17.7%13.2%21.1%
Return on capital——————————
Return on equity11.7%−7.8%11.7%5.6%−5.1%−12.6%−25.5%−53.2%−32.6%−15.6%
Return on assets10.0%−6.5%9.7%4.6%−4.5%−11.2%−20.7%−38.8%−21.8%−9.5%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: KORU Medical Systems' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with KORU Medical Systems.